To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 3, 2021

Primary Completion Date

June 2, 2025

Study Completion Date

June 2, 2026

Conditions

Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma

Interventions

DRUG

CAR-T cells

2×10\^6 CAR T cells/kg

Trial Locations (1)

RECRUITING

Universiti Kebangsaan Malaysia, Bandar Tun Razak

All Listed Sponsors

collaborator

Plutonet Sdn Bhd

UNKNOWN

lead

National University of Malaysia

OTHER